Healthcare provider profile · identity verified

John Frederick Shield, MD

Internal Medicine · SONORA, CA · NPI 1033189634

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Amlodipine Besylate	Amlodipine Besylate	583	136
Losartan Potassium	Losartan Potassium	456	118
Valsartan	Valsartan	455	114
Atorvastatin Calcium	Atorvastatin Calcium	436	114
Levothyroxine Sodium	Levothyroxine Sodium	355	79
Omeprazole	Omeprazole	321	81
Rosuvastatin Calcium	Rosuvastatin Calcium	307	86
Metoprolol Succinate	Metoprolol Succinate	252	63
Simvastatin	Simvastatin	236	58
Lisinopril	Lisinopril	231	58
Hydrochlorothiazide	Hydrochlorothiazide	226	54
Metformin Hcl Er	Metformin Hcl	178	54
Pantoprazole Sodium	Pantoprazole Sodium	155	35
Jardiance	Empagliflozin	151	33
Furosemide	Furosemide	146	40
Doxazosin Mesylate	Doxazosin Mesylate	135	37
Tamsulosin Hcl	Tamsulosin Hcl	130	35
Pioglitazone Hcl	Pioglitazone Hcl	126	28
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	124	27
Gabapentin	Gabapentin	122	35
Alendronate Sodium	Alendronate Sodium	120	26
Potassium Chloride	Potassium Chloride	112	34
Ozempic	Semaglutide	108	17
Allopurinol	Allopurinol	104	27
Famotidine	Famotidine	102	34
Montelukast Sodium	Montelukast Sodium	98	29
Carvedilol	Carvedilol	97	23
Eliquis	Apixaban	93	25
Sertraline Hcl	Sertraline Hcl	93	19
Metformin Hcl	Metformin Hcl	92	23
Fluticasone Propionate	Fluticasone Propionate	88	32
Clopidogrel	Clopidogrel Bisulfate	85	23
Ezetimibe	Ezetimibe	85	23
Atenolol	Atenolol	84	21
Pravastatin Sodium	Pravastatin Sodium	78	18
Albuterol Sulfate Hfa	Albuterol Sulfate	76	27
Spironolactone	Spironolactone	68	18
Fluoxetine Hcl	Fluoxetine Hcl	63	13
Donepezil Hcl	Donepezil Hcl	62	16
Glimepiride	Glimepiride	59	16
Spiriva Respimat	Tiotropium Bromide	59	11
Januvia	Sitagliptin Phosphate	58	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	55	15
Quetiapine Fumarate	Quetiapine Fumarate	55	13
Warfarin Sodium	Warfarin Sodium	52	13
Lovastatin	Lovastatin	51	11
Trazodone Hcl	Trazodone Hcl	49	suppressed
Lansoprazole	Lansoprazole	47	16
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	46	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	42	13
Citalopram Hbr	Citalopram Hydrobromide	40	suppressed
Irbesartan	Irbesartan	40	suppressed
Pregabalin	Pregabalin	38	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	38	11
Alprazolam	Alprazolam	37	suppressed
Glipizide Er	Glipizide	37	suppressed
Synthroid	Levothyroxine Sodium	37	suppressed
Benazepril Hcl	Benazepril Hcl	36	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	36	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	35	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	35	suppressed
Xarelto	Rivaroxaban	33	suppressed
Duloxetine Hcl	Duloxetine Hcl	32	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	32	suppressed
Mirtazapine	Mirtazapine	32	suppressed
Myrbetriq	Mirabegron	32	suppressed
Nifedipine Er	Nifedipine	31	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	28	28
Estradiol	Estradiol	27	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	27	suppressed
Tramadol Hcl	Tramadol Hcl	27	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	25	18
Cartia Xt	Diltiazem Hcl	24	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	24	suppressed
Arnuity Ellipta	Fluticasone Furoate	22	suppressed
Memantine Hcl	Memantine Hcl	22	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	21	suppressed
Bupropion Xl	Bupropion Hcl	21	suppressed
Paroxetine Hcl	Paroxetine Hcl	21	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	20	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	20	suppressed
Ventolin Hfa	Albuterol Sulfate	20	suppressed
Ibuprofen	Ibuprofen	19	suppressed
Meloxicam	Meloxicam	19	suppressed
Vascepa	Icosapent Ethyl	19	suppressed
Azithromycin	Azithromycin	18	16
Digoxin	Digoxin	18	suppressed
Farxiga	Dapagliflozin Propanediol	18	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	18	suppressed
Trulicity	Dulaglutide	17	suppressed
Breo Ellipta	Fluticasone/Vilanterol	16	suppressed
Hydralazine Hcl	Hydralazine Hcl	16	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	16	suppressed
Clonazepam	Clonazepam	15	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	15	suppressed
Bevespi Aerosphere	Glycopyrrolate/Formoterol Fum	14	suppressed
Clonidine Hcl	Clonidine Hcl	14	suppressed
Gemfibrozil	Gemfibrozil	14	suppressed
Glipizide	Glipizide	14	suppressed
Ipratropium Bromide	Ipratropium Bromide	14	suppressed
Levofloxacin	Levofloxacin	14	13
Fenofibrate	Fenofibrate	13	suppressed
Nitroglycerin	Nitroglycerin	13	12
Atrovent Hfa	Ipratropium Bromide	12	suppressed
Dilt-Xr	Diltiazem Hcl	12	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	12	suppressed
Prednisone	Prednisone	12	suppressed
Bupropion Hcl Sr	Bupropion Hcl	11	suppressed
Calcium Acetate	Calcium Acetate	11	suppressed
Cephalexin	Cephalexin	11	suppressed
Droplet Pen Needle	Pen Needle, Diabetic	11	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	11	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	11	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error